MA37464A1 - Anti-egfr antibodies and their uses - Google Patents

Anti-egfr antibodies and their uses

Info

Publication number
MA37464A1
MA37464A1 MA37464A MA37464A MA37464A1 MA 37464 A1 MA37464 A1 MA 37464A1 MA 37464 A MA37464 A MA 37464A MA 37464 A MA37464 A MA 37464A MA 37464 A1 MA37464 A1 MA 37464A1
Authority
MA
Morocco
Prior art keywords
antibodies
egfr
bind
present
egfr antibodies
Prior art date
Application number
MA37464A
Other languages
French (fr)
Other versions
MA37464B1 (en
Inventor
Christopher Daly
Gavin Thurston
Nicholas J Papadopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2013/047476 external-priority patent/WO2014004427A2/en
Publication of MA37464A1 publication Critical patent/MA37464A1/en
Publication of MA37464B1 publication Critical patent/MA37464B1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des anticorps qui se lient à egfr et des procédés de son utilisation. Selon certains modes de réalisation de l'invention, les anticorps sont des anticorps complètement humains qui se lient à l'egfr humain avec une affinité élevée. Dans certains modes de réalisation, les anticorps de la présente invention sont aptes à inhiber la croissance de cellules tumorales exprimant des taux élevés d'egfr et/ou induisant une cytotoxicité à médiation cellulaire dépendante d'un anticorps (adcc) de telles cellules. Les anticorps de l'invention sont utiles pour le traitement de divers cancers, ainsi que pour d'autres troubles associés à egfr.The present invention relates to antibodies that bind to egfr and methods of its use. According to some embodiments of the invention, the antibodies are fully human antibodies that bind to human egfr with high affinity. In some embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of egfr and / or inducing antibody-dependent cell-mediated cytotoxicity (adcc) of such cells. The antibodies of the invention are useful for the treatment of various cancers, as well as for other egfr-associated disorders.

MA37464A 2012-06-25 2013-06-25 Anti-egfr antibodies and their uses MA37464B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261663984P 2012-06-25 2012-06-25
PCT/US2013/047476 WO2014004427A2 (en) 2012-06-25 2013-06-25 Anti-egfr antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MA37464A1 true MA37464A1 (en) 2016-03-31
MA37464B1 MA37464B1 (en) 2018-03-30

Family

ID=56073199

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37464A MA37464B1 (en) 2012-06-25 2013-06-25 Anti-egfr antibodies and their uses

Country Status (1)

Country Link
MA (1) MA37464B1 (en)

Also Published As

Publication number Publication date
MA37464B1 (en) 2018-03-30

Similar Documents

Publication Publication Date Title
MA39313A1 (en) Anti-egfrviii antibodies and their uses in the treatment of various cancers
PH12014502437A1 (en) Anti-egfr antibodies and uses threof
MA45125B1 (en) Anti-alpha-synuclein antibodies and their uses
MA38194B1 (en) Anti-ceacam5 antibodies and their uses
MA40497A (en) ANTIBODIES AND CHEMERICAL ANTIGENIC RECEPTORS SPECIFIC TO CD19
MX2022001086A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof.
MA42622B1 (en) LIAISONS IN TIGIT AND THEIR USES
MA40309A1 (en) Anti-cd73 Antibodies and Their Uses
PL1830881T3 (en) Combining therapies targeting multiple toll-like receptors and use thereof
EA201071300A1 (en) ANTIBODIES TO CXCR4
IL250832B (en) A mixture of beta-glucosylceramide and beta-lactosylceramide for use in the treatment of colitis
MA32566B1 (en) ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUSES AND USES THEREOF
MY185858A (en) Specific binding proteins and uses thereof
MA33402B1 (en) COMPOSITIONS AND METHODS FOR TARGETING COMPLEMENT C3B PROTEIN BY ANTIBODIES
SI2269656T1 (en) Selected antibodies binding to aminophospholipids and their use in treatment, such as cancer
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
MY150709A (en) Human cytomegalovirus neutralising antibodies and use thereof
MA33276B1 (en) Cadherine-17 antibodies
CR20210197A (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
MX2010003013A (en) Inhibition of angiogenesis.
MX2022002682A (en) Anti-cd73 antibodies.
MX2023004869A (en) Antibodies against sars-cov-2 and uses thereof.
MA37464B1 (en) Anti-egfr antibodies and their uses
FR2981945B1 (en) HUMAN MASTOCYTE LINES, PREPARATION AND USES
MA47976B1 (en) ANTIBODIES DIRECTED AGAINST TREM2 AND THEIR USE